With some projections suggesting specialty drug costs could account for roughly 50 percent of all drug spending by 2020, Kimberly Firtz, PharmD, says outcomes reporting is more important than ever.
Firtz in her write up published Wednesday on Specialty Pharmacy Times stresses the necessity of reporting positive clinical outcomes for patients.
“As an employer group, if I’m paying $7,000 for a Copaxone prescription, I need to make sure that it’s working,” she writes. “By the same token, if I’m a pharmaceutical manufacturer of an orphan drug, I need to demonstrate continued safety and efficacy for the medication, especially if my initial clinical trial size was limited.”
To read Firtz’s full article on Specialty Pharmacy Times, click here.